Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 3.6% – Here’s What Happened

Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) traded up 3.6% on Friday. The stock traded as high as $16.09 and last traded at $16.03. 86,519 shares traded hands during mid-day trading, a decline of 31% from the average session volume of 125,349 shares. The stock had previously closed at $15.48.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on GLSI shares. HC Wainwright raised their target price on Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Weiss Ratings raised Greenwich LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Greenwich LifeSciences presently has an average rating of “Hold” and an average price target of $69.00.

Greenwich LifeSciences Trading Up 3.6%

The firm has a fifty day simple moving average of $16.63 and a 200-day simple moving average of $19.89. The stock has a market cap of $235.32 million, a price-to-earnings ratio of -10.41 and a beta of 1.46.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.06. On average, equities analysts predict that Greenwich LifeSciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Institutional Trading of Greenwich LifeSciences

A number of large investors have recently made changes to their positions in the company. Ancora Advisors LLC acquired a new position in shares of Greenwich LifeSciences during the 2nd quarter worth about $252,000. BlackRock Inc. bought a new position in shares of Greenwich LifeSciences in the 2nd quarter valued at about $11,398,000. Deutsche Bank AG bought a new position in shares of Greenwich LifeSciences in the 2nd quarter valued at about $126,000. Bank of New York Mellon Corp acquired a new stake in shares of Greenwich LifeSciences in the second quarter valued at about $1,124,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Greenwich LifeSciences in the second quarter valued at about $458,000. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies designed to reduce the risk of breast cancer recurrence. The company’s lead product candidate is GLSI-100, an investigational vaccine combining the HER2-derived peptide GP2 with granulocyte-macrophage colony-stimulating factor (GM-CSF).

GLSI-100 is being developed as an adjuvant therapy for patients with HER2-positive breast cancer who have completed standard treatment, including trastuzumab.